BACKGROUND AND AIMS: This study addresses whether antibiotic prophylaxis is beneficial for acute necrotizing pancreatitis. METHODS: This randomized, controlled trial enrolled 276 patients with severe acute pancreatitis. There were 56 patients with 30% or more necrosis proved by contrast-enhanced computerized tomography who were eligible for randomization: 29 in the study group and 27 in the control group, who receivedi.v. imipenem-cilastatin (3 x 500 mg/day) within 72 h of the onset of symptoms for 7-14 days, and no antibiotic prophylaxis, respectively. The primary end-point was the incidence of infectious complication. The secondary end-points were mortality, the incidence of necrosectomy for infected necrosis, the incidence of organ complication and hospital courses. RESULTS: Characteristics of baseline data were similar in the two groups. No significant differences were found in the incidence of infected pancreatic necrosis (37% vs 27.6%), mortality (10.3% vs 14.8%) and the incidence of operative necrosectomy (29.6% vs 34.6%) between the study group and the control group (P > 0.05). The incidence of extrapancreatic infections, organ complications and hospital courses between the groups were also not significantly different. However, a significantly increased incidence of fungal infection was observed in the study group versus the control group (36.1% vs 14.2%, P < 0.05). CONCLUSION: There was no benefit in the outcomes when antibiotic prophylaxis was routinely used in patients with acute necrotizing pancreatitis.
RCT Entities:
BACKGROUND AND AIMS: This study addresses whether antibiotic prophylaxis is beneficial for acute necrotizing pancreatitis. METHODS: This randomized, controlled trial enrolled 276 patients with severe acute pancreatitis. There were 56 patients with 30% or more necrosis proved by contrast-enhanced computerized tomography who were eligible for randomization: 29 in the study group and 27 in the control group, who received i.v. imipenem-cilastatin (3 x 500 mg/day) within 72 h of the onset of symptoms for 7-14 days, and no antibiotic prophylaxis, respectively. The primary end-point was the incidence of infectious complication. The secondary end-points were mortality, the incidence of necrosectomy for infected necrosis, the incidence of organ complication and hospital courses. RESULTS: Characteristics of baseline data were similar in the two groups. No significant differences were found in the incidence of infected pancreatic necrosis (37% vs 27.6%), mortality (10.3% vs 14.8%) and the incidence of operative necrosectomy (29.6% vs 34.6%) between the study group and the control group (P > 0.05). The incidence of extrapancreatic infections, organ complications and hospital courses between the groups were also not significantly different. However, a significantly increased incidence of fungal infection was observed in the study group versus the control group (36.1% vs 14.2%, P < 0.05). CONCLUSION: There was no benefit in the outcomes when antibiotic prophylaxis was routinely used in patients with acute necrotizing pancreatitis.
Authors: Adrian C Vlada; Bradley Schmit; Andrew Perry; Jose G Trevino; Kevin E Behrns; Steven J Hughes Journal: HPB (Oxford) Date: 2013-10 Impact factor: 3.647
Authors: Cheryl Li Ling Lim; Winnie Lee; Yi Xin Liew; Sarah Si Lin Tang; Maciej Piotr Chlebicki; Andrea Lay-Hoon Kwa Journal: J Gastrointest Surg Date: 2015-01-22 Impact factor: 3.452
Authors: Gautham Srinivasan; L Venkatakrishnan; Swaminathan Sambandam; Gursharan Singh; Maninder Kaur; Krishnaveni Janarthan; B Joseph John Journal: J Family Med Prim Care Date: 2016 Oct-Dec